Ginwa Enterprise(Group) Inc. (600080.SH) announced its 2024 semi-annual report on August 16th. During the reporting period, the company achieved revenue of 246 million yuan, a year-on-year decrease of 3.68%; net income attributable to shareholders of listed companies was 9.4629 million yuan, a year-on-year increase of 211.01%, and net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 10.0314 million yuan, a year-on-year decrease of 42.39%; the basic earnings per share was 0.0261 yuan.
The company's leading product Jintiange capsules is a national first-class new drug. After years of promotion, it has become a first-line traditional Chinese medicine for orthopedic clinical treatment; Transfer Factor series products are biological drugs that improve human immunity; Children's series products include children's cough syrup; The general medicine series mainly includes glycerin enema, norfloxacin capsules, mefenamic acid capsules and other varieties. The company's major products have formed a competitive advantage of stable quality, safety, and reliability in many years of operation.
